Table 4 shows for the prodromal Alzheimer’s disease cohort (Aβ+ column) without additional markers an estimated sample size of 729 (95% CI = 444–1364) for the MMSE, and 486 (95% CI = 348–737) for the CDR-SB. Estimated sample sizes were smallest when restricting enrolment to prodromal Alzheimer’s disease participants with abnormal p-tau, abnormal HV and abnormal small-world status (Aβ+σ+ p-tau+ HV+, Table 4). Here, MAPT is linked to Alzheimer disease.